Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 8/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313541 | 0.93 | MDM2 (0.44) | TLR2TLR1MDM2ITGB3ITGA2B | |
| SCHEMBL30313463 | 0.92 | TLR2 (0.47) | TLR2TLR1MDM2ITGB3ITGA2B | |
| SCHEMBL30313491 | 0.90 | MMP1 (0.43) | TLR2TLR1MDM2ITGB3ITGA2B | |
| SCHEMBL30313483 | 0.90 | MMP1 (0.44) | TLR2TLR1MDM2ITGB3ITGA2B | |
| SCHEMBL31297113 | 0.87 | F2 (0.47) | TLR2MDM2ACEFAPPRCP | |
| SCHEMBL30313548 | 0.87 | MMP1 (0.42) | TLR2TLR1MDM2FAP | |
| SCHEMBL30391539 | 0.86 | CMA1 (0.43) | TLR2TLR1MDM2ITGB3ITGA2B | |
| SCHEMBL23039371 | 0.84 | TLR2 (0.46) | TLR2TLR1ITGB3ITGA2BKMT2A | |
| SCHEMBL22026762 | 0.84 | TLR2 (0.46) | TLR2TLR1ITGB3ITGA2BKMT2A | |
| SCHEMBL22127964 | 0.84 | TLR2 (0.46) | TLR2TLR1ITGB3ITGA2BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-11613558-B2 | Peptides and pharmaceutical compositions for treating eye diseases | YUYU PHARMA, INC. (KR) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312648-A1 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | VIP, IAPP, SCTR | TLR2 1445/4885TLR1 1239/4885MDM2 3847/4885 |
| US-11613558-B2 | Peptides and pharmaceutical compositions for treating eye diseases | VIP, IAPP, SCTR | TLR2 1445/4885TLR1 1239/4885MDM2 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.